Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Kurmasheva RT, Bandyopadhyay A, Favours E, Del Pozo V, Ghilu S, Phelps DA, Erickson SW, Peer CJ, Figg WD, Smith MA, Houghton PJ. Kurmasheva RT, et al. Among authors: erickson sw. Pediatr Blood Cancer. 2019 Aug;66(8):e27820. doi: 10.1002/pbc.27820. Epub 2019 May 16. Pediatr Blood Cancer. 2019. PMID: 31099166 Free PMC article.
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
Kolb EA, Houghton PJ, Kurmasheva RT, Mosse YP, Maris JM, Erickson SW, Guo Y, Teicher BA, Smith MA, Gorlick R. Kolb EA, et al. Among authors: erickson sw. Pediatr Blood Cancer. 2020 May;67(5):e28098. doi: 10.1002/pbc.28098. Epub 2020 Jan 23. Pediatr Blood Cancer. 2020. PMID: 31975571 Free PMC article.
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.
Kurmasheva RT, Erickson SW, Earley E, Smith MA, Houghton PJ. Kurmasheva RT, et al. Among authors: erickson sw. Pediatr Blood Cancer. 2021 Feb;68(2):e28772. doi: 10.1002/pbc.28772. Epub 2020 Oct 22. Pediatr Blood Cancer. 2021. PMID: 33089597 Free PMC article.
In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC).
Kurmasheva RT, Erickson SW, Han R, Teicher BA, Smith MA, Roth M, Gorlick R, Houghton PJ. Kurmasheva RT, et al. Among authors: erickson sw. Pediatr Blood Cancer. 2021 Nov;68(11):e29304. doi: 10.1002/pbc.29304. Epub 2021 Aug 28. Pediatr Blood Cancer. 2021. PMID: 34453478 Free PMC article.
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF. Lowery CD, et al. Among authors: erickson sw. Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18. Clin Cancer Res. 2019. PMID: 30563935 Free PMC article.
80 results